Galaxy Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry
Recruiting
- Conditions
- AneurysmAneurysm, Ruptured
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Galaxy Therapeutics INC
- Target Recruit Count
- 200
- Registration Number
- NCT05880680
- Locations
- 🇨🇴
Angiosur, Itagüi, Medellín, Colombia
🇳🇿Auckland City Hospital, Auckland, New Zealand
🇵🇰Punjab Institute of Neuroscience (PINS), Lahore, Pakistan
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
Phase 3
Recruiting
- Conditions
- Intracranial Aneurysm
- Interventions
- Device: The SEAL™ Saccular Endovascular Aneurysm Lattice System
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Galaxy Therapeutics INC
- Target Recruit Count
- 279
- Registration Number
- NCT05831202
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸Endeavor Health - Evanston Hospital, Evanston, Illinois, United States
🇺🇸Endeavor Health - Northwest Community Hospital, Arlington Heights, Illinois, United States
Pre-SEAL™IT: Saccular Endovascular Aneurysm Lattice System First In Human Interventional Trial
Not Applicable
Completed
- Conditions
- Aneurysm, RupturedAneurysmAneurysms Saccular
- Interventions
- Device: SEAL Device
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Galaxy Therapeutics INC
- Target Recruit Count
- 26
- Registration Number
- NCT05686733
- Locations
- 🇨🇴
Clinicas Las Americas, Medellin, Antioquia, Colombia